Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ABBV

Abbvie Inc

Jun 10 • 12:50PM ET

225.77

+0.35 0.16 %

Healthcare • Drug Manufacturers - General • USA • Mega • NYSE

Jun 08, 8:36 AMAbbVie reports EHA 2026 Phase 3 data showing epcoritamab improves PFS but not OS in relapsed/refractory large B-cell lymphoma

Peers: LLY MRK PFE JNJ BMY AZN NVS AMGN NVO GILD

| Held by: VTI VOO IVV SPY VTV XLV VIG IWF VYM VHT

Scroll to Statements

Index	S&P 500	P/E	111.36	EPS (ttm)	2.03	Insider Own	0.12%	Shs Outstand	1.77B	Perf Week	3.98%
Market Cap	398.90B	Forward P/E	13.86	EPS next Y	16.29	Insider Trans	-2.14%	Shs Float	1.76B	Perf Month	11.34%
Enterprise Value	462.41B	PEG	0.64	EPS next Q	3.76	Inst Own	76.14%	Short Float	1.31%	Perf Quarter	-0.84%
Income	3.60B	P/S	6.35	EPS this Y	42.67%	Inst Trans	-0.26%	Short Ratio	3.55	Perf Half Y	1.19%
Sales	62.82B	P/B	-	EPS next Y	14.15%	ROA	2.64%	Short Interest	23.16M	Perf YTD	-1.19%
Book/sh	-3.77	P/C	42.48	EPS next 5Y	21.56%	ROE	15221.82%	52W High	244.81 -7.78%	Perf Year	19.14%
Cash/sh	5.32	P/FCF	19.96	EPS past 3/5Y	-29.11% -2.81%	ROIC	6.21%	52W Low	181.73 24.24%	Perf 3Y	63.39%
Dividend Est.	6.84 (3.03%)	EV/EBITDA	15.84	Sales past 3/5Y	1.75% 5.95%	Gross Margin	70.58%	Volatility	2.57% 2.48%	Perf 5Y	94.23%
Dividend TTM	6.74 (2.99%)	EV/Sales	7.36	EPS Y/Y TTM	-13.63%	Oper. Margin	33.58%	ATR (14)	5.51	Perf 10Y	270.12%
Dividend Ex-Date	Apr 15, 2026	Quick Ratio	0.68	Sales Y/Y TTM	9.50%	Profit Margin	5.72%	RSI (14)	64.36	Recom	1.67
Dividend Gr. 3/5Y	5.21% 6.56%	Current Ratio	0.80	EPS Q/Q	-46.38%	SMA20	4.23%	Beta	0.30	Target Price	253.85
Payout	281.66%	Debt/Eq	-	Sales Q/Q	12.43%	SMA50	7.30%	Rel Volume	0.38	Prev Close	225.42
Employees	57000	LT Debt/Eq	-	Earnings	Apr 29 BMO	SMA200	2.55%	Avg Volume	6.51M	Price	225.77
IPO	Dec 10, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.23% 1.93%	Trades		Volume	1,330,899	Change	0.16%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-26	Upgrade	BofA Securities	Neutral → Buy	$234
Apr-21-26	Initiated	Canaccord Genuity	Buy	$262
Feb-25-26	Initiated	RBC Capital Mkts	Outperform	$260
Feb-20-26	Initiated	Barclays	Overweight	$275
Jan-08-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-07-26	Resumed	UBS	Neutral	$240
Dec-10-25	Upgrade	HSBC Securities	Hold → Buy	$265
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$280
Nov-04-25	Downgrade	DZ Bank	Buy → Hold	$237
Oct-14-25	Downgrade	Erste Group	Buy → Hold
Oct-01-25	Downgrade	HSBC Securities	Buy → Hold
Sep-17-25	Upgrade	Berenberg	Hold → Buy	$270
Aug-12-25	Resumed	Piper Sandler	Overweight	$231
Aug-07-25	Upgrade	Daiwa Securities	Neutral → Outperform	$214
May-14-25	Downgrade	Citigroup	Buy → Neutral	$205
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight	$210
Dec-10-24	Resumed	BofA Securities	Neutral	$191
Dec-05-24	Downgrade	Daiwa Securities	Outperform → Neutral	$180
Nov-22-24	Upgrade	Leerink Partners	Market Perform → Outperform	$206
Nov-15-24	Initiated	Wolfe Research	Outperform	$205

Show Previous Ratings

Today 08:00AM	Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics (PR Newswire)
Jun-08-26 03:49PM	Why Is Lilly Stock Growing Like A Silicon Valley Tech Darling? (Trefis)
09:07AM	Can MariTide Save Amgen Stock From Its Fading Blockbusters? (Trefis)
08:55AM	Is AbbVie Stock The Right Defensive Pick In This Volatile Market? (Trefis)
08:00AM	AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 (PR Newswire)
06:55PM	Loading…
Jun-05-26 06:55PM	Is Amgen An Undervalued Stock Or Value Trap? (Trefis)
Jun-04-26 04:23PM	75% Upside For LLY Stock? (Trefis)
07:06AM	AbbVie receives EC approval for Aquipta to treat migraine (Pharmaceutical Business Review)
Jun-03-26 03:30AM	Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick. (Barrons.com)
03:15AM	Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors (TMX Newsfile)
Jun-02-26 08:00AM	AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (PR Newswire)
04:00AM	AbbVie Announces European Commission Approval of AQUIPTA (atogepant) for the Acute Treatment of Migraine in Adults (PR Newswire)
Jun-01-26 09:04PM	Glenmark Pharmaceuticals Ltd (BOM:532296) Q4 2026 Earnings Call Highlights: Strong Revenue ... (GuruFocus.com)
12:41PM	ASCO26: Platinum-resistant ADC leader Elahere stumbles in platinum-sensitive disease (Pharmaceutical Technology)
May-29-26 08:00AM	AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia (PR Newswire)
06:17AM	Loading…
06:17AM	Allogene CEO to step down; Agios drug fails key test (BioPharma Dive)
May-28-26 06:33PM	Akari Therapeutics Highlights 1st ASCO Abstract Acceptance (IPO-Edge.com)
12:53PM	VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC (Exec Edge)
05:30AM	J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge? (The Wall Street Journal)
May-27-26 06:18PM	U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options (PR Newswire)
04:26PM	ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug (Stocktwits)
May-22-26 08:00AM	AbbVie Announces Positive CHMP Opinion for MAVIRET (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection (PR Newswire)
May-21-26 06:46PM	AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline (PR Newswire)
04:10PM	Allergan Aesthetics Receives Positive CHMP Opinion for Boey (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults (PR Newswire)
May-06-26 10:07AM	This Small Biotech - Taking On AbbVie, Novartis And Sanofi - Just Catapulted Into A Breakout (Investor's Business Daily)
08:26AM	DDW 2026: key readouts from the conference (Clinical Trials Arena)
08:00AM	AbbVie to Present at the Bank of America Securities Healthcare Conference (PR Newswire)
May-05-26 08:05AM	AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week (PR Newswire)
May-01-26 05:01PM	Watch: Why Investors Are Still Worried About AbbVie (The Wall Street Journal)
Apr-30-26 03:00PM	AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec (GlobeNewswire)
09:36AM	Loading…
09:36AM	Meta downgraded, Qualcomm upgraded: Wall Street's top analyst calls (The Fly)
07:01AM	Siemens, Diageo, Oxbo and others open US facilities in April (Manufacturing Dive)
Apr-29-26 12:49PM	AbbVie Inc. Q1 2026 Earnings Call Summary (Moby)
11:33AM	AbbVie Raises 2026 Outlook To $14.28 As Q1 Earnings Beat Estimates (GuruFocus.com)
09:11AM	AbbVie beats Q1 2026 earnings, raises full-year forecast (Quartz)
09:11AM	AbbVie beat earnings expectations and raised its outlook as newer drugs offset Humira's decline (Quartz)
08:48AM	AbbVie Hikes Earnings Outlook As Immunology Duo Outperforms (Investor's Business Daily)
08:41AM	AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock. (Barrons.com)
08:34AM	AbbVie shares gain on earnings beat, raised guidance (Investing.com)
08:32AM	AbbVie Raises FY Guidance on Immunology, Neuroscience Growth (The Wall Street Journal)
08:01AM	AbbVie: Q1 Earnings Snapshot (Associated Press)
07:47AM	AbbVie Reports First-Quarter 2026 Financial Results (PR Newswire)
05:03AM	Big-tech earnings bonanza after closing bell (MarketWatch)
04:22AM	Stock Market Today: Dow, S&P 500 and Nasdaq set to rise ahead of host of tech earnings; Fed interest-rate decision due (MarketWatch)
Apr-28-26 08:00AM	AbbVie Submits Application to FDA for Upadacitinib (RINVOQ) for Adults and Adolescents with Severe Alopecia Areata (PR Newswire)
Apr-27-26 10:49AM	Week ahead: Big Tech earnings, Fed decision, and an oil crisis set up Wall Street's biggest test of the year (Proactive)
08:05AM	AbbVie Submits Regulatory Application to FDA for SKYRIZI (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease (PR Newswire)
07:01AM	How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise (Investor's Business Daily)
Apr-23-26 04:05PM	AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S. (PR Newswire)
07:38AM	Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus (Manufacturing Dive)
06:36AM	AbbVie opts for North Carolina to house $1.4bn manufacturing site (Pharmaceutical Technology)
Apr-22-26 12:02PM	AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus (PR Newswire)
Apr-20-26 12:41PM	Trump Signs Psychedelic Drugs Order. 4 Stocks That Are Surging. (Barrons.com)
Apr-14-26 08:50AM	Erin Lichy Gets Real About Her Natrelle Breast Augmentation (PR Newswire)
Apr-13-26 08:03PM	Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1? (Quartz)
09:11AM	This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success. (Barrons.com)
08:07AM	AbbVie bets on Chinese biopharmas pain pipeline in $745m bid (Pharmaceutical Technology)
Apr-12-26 07:15AM	AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE) in Platinum-Sensitive Ovarian Cancer (PSOC) at SGO 2026 (PR Newswire)
Apr-10-26 05:28PM	This Startup's Psoriasis Drug Studies Have Lifted Its Stock (Barrons.com)
Apr-08-26 08:00AM	BOTOX Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year (PR Newswire)
Apr-07-26 03:35PM	Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization (Exec Edge)
09:53AM	The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it. (MarketWatch)
09:00AM	Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin (PR Newswire)
Apr-02-26 03:39PM	Trump Slaps 100% Tariffs on Some Drug Imports. What to Know. (Barrons.com)
Mar-31-26 04:36PM	US Corporate Taxes Drop $65 Billion After Trump's $3.4 Trillion Tax Law (GuruFocus.com)
08:05AM	Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting (PR Newswire)
08:00AM	AbbVie to Host First-Quarter 2026 Earnings Conference Call (PR Newswire)
06:00AM	Trumps Tax Cut Delivers at Least $65 Billion Windfall to Corporations (Bloomberg)
Mar-30-26 08:00AM	Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD) (PR Newswire)
Mar-27-26 10:00AM	AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting (PR Newswire)
01:01AM	ABBV- An Attractive Income Stock in this Turbulent Market (MoneyShow)
Mar-26-26 04:00AM	Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC) (PR Newswire)
03:00AM	Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVEDERM at AMWC Monaco (PR Newswire)
Mar-24-26 08:00AM	AbbVie Named Official Pharmaceutical Partner of Major League Baseball (PR Newswire)
Mar-19-26 11:39AM	Long-only funds are buying non-US stocks, BofA says (Investing.com)
03:00AM	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions (PR Newswire)
Mar-18-26 08:05AM	J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections (BioPharma Dive) -5.20%
Mar-12-26 04:51PM	Why Investors Aren't Fleeing to Safe-Haven Stocks (The Wall Street Journal)
08:48AM	UCBs Bimzelx bests Skyrizi in Phase III PsA study, but analysts sceptical (Clinical Trials Arena)
Mar-11-26 05:33AM	Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial (BioPharma Dive)
Mar-10-26 07:00AM	Xenon hits a home run in epilepsy; FDA restarts review of Duchenne cell therapy (BioPharma Dive)
Mar-09-26 10:11AM	AbbVie's Early Obesity Drug Data Shows Up To 10% Weight Loss (Benzinga)
09:50AM	Here's Why AbbVie (ABBV) is a Strong Momentum Stock (Zacks)
09:00AM	AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:10AM	Quiet Outperformance From an Overlooked Dividend ETF (MarketBeat)
08:00AM	AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults (PR Newswire)
04:46AM	AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn's Disease (Insider Monkey)
12:39AM	1 Momentum Stock to Consider Right Now and 2 We Ignore (StockStory)
Mar-08-26 09:54AM	Retirees Take Note: DGRO Yields 2.4%, Has Raised Its Dividend Every Single Year for Over a Decade (24/7 Wall St.)
09:00AM	This 5-Star ETF Pays Monthly Dividends and Has Never Missed in 19 Years (24/7 Wall St.)
Mar-06-26 03:48PM	Jobs Report Just Dented Most Bulletproof Sector ETF In The Market (Benzinga)
11:30AM	AbbVie (ABBV) Up 6.1% Since Last Earnings Report: Can It Continue? (Zacks)
08:25AM	These 3 Cash Flow Machines Provide Stability in Uncertain Markets (MarketBeat)
08:21AM	Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? (Zacks)
07:39AM	Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026? (Zacks)
12:10AM	REGENXBIO Q4 Earnings Call Highlights (MarketBeat)
Mar-05-26 11:02PM	AbbVie (ABBV): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
05:45PM	AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
02:02PM	Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience (GuruFocus.com)
Mar-04-26 08:00AM	ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS (PR Newswire)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders such as Parkinson's disease; metabolic disorders, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

CEO & Chairman of the BoardMr. Robert A. Michael CPA

Executive VP & CFOMr. Scott T. Reents

Executive VP & COODr. Azita Saleki-Gerhardt Ph.D.

Executive VP of Research & Development and Chief Scientific OfficerDr. Roopal B. Thakkar M.D.

Executive VP & Chief Commercial OfficerMr. Jeffrey Ryan Stewart

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBERT J ALPERN	Director	May 26 '26	Proposed Sale	214.00	13,000	2,781,991		May 26 04:10 PM
Purdue David Ryan	SVP, Controller	Mar 04 '26	Sale	233.56	5,230	1,221,519	2,654	Mar 06 05:05 PM
David R. Purdue	Officer	Mar 04 '26	Proposed Sale	233.56	5,230	1,221,519		Mar 06 05:04 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 02 '26	Sale	234.39	18,668	4,375,549	4,619	Mar 03 06:10 PM
PERRY C SIATIS	Officer	Mar 02 '26	Proposed Sale	234.39	18,668	4,375,585		Mar 02 04:05 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Option Exercise	172.62	22,381	3,863,458	60,518	Feb 27 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Sale	230.00	22,381	5,147,630	38,137	Feb 27 05:00 PM
PERRY C SIATIS	Officer	Feb 25 '26	Proposed Sale	230.00	22,381	5,147,630		Feb 25 04:49 PM
Richard A. Gonzalez	Former Director	Aug 22 '25	Proposed Sale	210.84	62,755	13,231,264		Aug 22 06:02 PM
Richard A. Gonzalez	Former Director	Aug 21 '25	Proposed Sale	211.04	90,000	18,993,948		Aug 21 06:04 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Option Exercise	54.86	42,370	2,324,418	219,662	Aug 14 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Sale	198.42	42,370	8,407,055	177,292	Aug 14 05:00 PM
AZITA SALEKI-GERHARDT	Officer	Aug 12 '25	Proposed Sale	198.42	42,370	8,407,068		Aug 12 07:22 PM
Richard A. Gonzalez	Former Director	Aug 01 '25	Proposed Sale	195.83	61,500	12,043,268		Aug 08 05:03 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Aug 05 '25	Sale	198.51	13,295	2,639,253	58,247	Aug 07 05:00 PM
NICHOLAS DONOGHOE	Officer	Aug 05 '25	Proposed Sale	198.51	13,299	2,639,966		Aug 05 04:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your Finviz experience